Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib as first-line treatment for Philadelphia chromosome-positive chronic myeloid leukemia in early chronic phase
2007-000597-22Phase 2Active
- Sponsor
- GIMEMA
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by GIMEMA. Primary endpoint: Complete cytogenetic response rate at 1 year. Started May 2007; status: active.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2007-000597-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000597-22.